Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Novo Nordisk’s oral Wegovy wins FDA approval, outperforming rivals in weight loss. Discover why NVO stock is undervalued now.

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.